| Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer (NCT05244434) | City of Hope Medical Center | 2022-07-03 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer (NCT05319873) | Jonsson Comprehensive Cancer Center | 2022-04-07 |
| A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer (NCT05215769) | Ohio State University Comprehensive Cancer Center | 2022-03-30 |
| Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer (NCT05177796) | M.D. Anderson Cancer Center | 2022-03-11 |
| CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer (NCT05081492) | City of Hope Medical Center | 2021-10-18 |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (NCT04673448) | University of Washington | 2021-10-18 |
| Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel (NCT04862585) | Ohio State University Comprehensive Cancer Center | 2021-10-07 |
| Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer (NCT04750473) | Emory University | 2021-07-16 |
| Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases (NCT04647916) | SWOG Cancer Research Network | 2021-06-08 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer (NCT04498520) | Pamela Munster | 2021-03-31 |
| Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer (NCT04190056) | University of California, San Francisco | 2021-03-11 |
| Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial (NCT04756505) | M.D. Anderson Cancer Center | 2021-03-07 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases (NCT04752267) | University of Southern California | 2021-02-15 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (NCT04789668) | M.D. Anderson Cancer Center | 2021-01-15 |
| Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer (NCT04418219) | Thomas Jefferson University | 2020-12-21 |
| Nipple Aspirate Fluid in Detecting Breast Cancer (NCT03715959) | Ohio State University Comprehensive Cancer Center | 2020-12-10 |
| Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring (NCT04906369) | Mayo Clinic | 2020-11-16 |
| T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer (NCT04351230) | Academic and Community Cancer Research United | 2020-11-11 |
| Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer (NCT04205071) | Ohio State University Comprehensive Cancer Center | 2020-11-01 |
| Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study (NCT04316117) | ECOG-ACRIN Cancer Research Group | 2020-09-15 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer (NCT04090567) | M.D. Anderson Cancer Center | 2020-07-28 |
| INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (NCT04445844) | Mridula George, MD | 2020-07-13 |
| Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors (NCT04526587) | Roswell Park Cancer Institute | 2020-07-03 |
| Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases (NCT04585724) | Emory University | 2020-06-12 |
| Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. (NCT04305834) | City of Hope Medical Center | 2020-03-25 |
| T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (NCT03554044) | University of California, San Francisco | 2020-02-05 |
| Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer (NCT04249167) | Mayo Clinic | 2020-01-23 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (NCT03987555) | Wake Forest University Health Sciences | 2019-11-11 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574) | National Cancer Institute (NCI) | 2019-07-16 |
| Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer (NCT03207529) | M.D. Anderson Cancer Center | 2019-06-07 |
| Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study (NCT04256941) | M.D. Anderson Cancer Center | 2019-05-31 |
| Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer (NCT03853707) | City of Hope Medical Center | 2019-03-04 |
| A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer (NCT03803761) | National Cancer Institute (NCI) | 2019-02-13 |
| Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (NCT03691493) | Emory University | 2019-02-08 |
| Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice (NCT04297384) | Roswell Park Cancer Institute | 2019-02-06 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826) | National Cancer Institute (NCI) | 2018-09-24 |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer (NCT03723928) | SWOG Cancer Research Network | 2018-09-17 |
| Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer (NCT03774472) | M.D. Anderson Cancer Center | 2018-08-20 |
| M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (NCT03579472) | M.D. Anderson Cancer Center | 2018-05-30 |
| Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer (NCT03544125) | OHSU Knight Cancer Institute | 2018-05-03 |
| Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT03524170) | M.D. Anderson Cancer Center | 2018-04-30 |
| IACS-010759 in Advanced Cancers (NCT03291938) | M.D. Anderson Cancer Center | 2017-11-13 |
| Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer (NCT03106077) | M.D. Anderson Cancer Center | 2017-06-05 |
| Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival (NCT02364557) | NRG Oncology | 2014-12-24 |
| Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer (NCT01334021) | M.D. Anderson Cancer Center | 2011-05-31 |
| Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer (NCT00338728) | M.D. Anderson Cancer Center | 2003-10-03 |